Home Cart 0 Sign in  
X

[ CAS No. 102-51-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 102-51-2
Chemical Structure| 102-51-2
Chemical Structure| 102-51-2
Structure of 102-51-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 102-51-2 ]

Related Doc. of [ 102-51-2 ]

Alternatived Products of [ 102-51-2 ]

Product Details of [ 102-51-2 ]

CAS No. :102-51-2 MDL No. :MFCD00047837
Formula : C7H10N2O Boiling Point : -
Linear Structure Formula :- InChI Key :AGAHETWGCFCMDK-UHFFFAOYSA-N
M.W : 138.17 Pubchem ID :153404
Synonyms :

Calculated chemistry of [ 102-51-2 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.14
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 2.0
Molar Refractivity : 41.74
TPSA : 61.27 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.7 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.25
Log Po/w (XLOGP3) : 0.62
Log Po/w (WLOGP) : 0.88
Log Po/w (MLOGP) : 0.53
Log Po/w (SILICOS-IT) : 0.39
Consensus Log Po/w : 0.73

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.47
Solubility : 4.73 mg/ml ; 0.0343 mol/l
Class : Very soluble
Log S (Ali) : -1.48
Solubility : 4.56 mg/ml ; 0.033 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.78
Solubility : 2.3 mg/ml ; 0.0167 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.18

Safety of [ 102-51-2 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362+P364-P403+P233-P501 UN#:2811
Hazard Statements:H301-H311-H331-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 102-51-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 102-51-2 ]
  • Downstream synthetic route of [ 102-51-2 ]

[ 102-51-2 ] Synthesis Path-Upstream   1~47

  • 1
  • [ 102-51-2 ]
  • [ 41292-65-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 7, p. 2620 - 2623
  • 2
  • [ 68-12-2 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
YieldReaction ConditionsOperation in experiment
93% at 120℃; for 6 h; General procedure: To a 10mL three-necked round bottle was charged with 1a (0.54 g, 5 mmol), imidazolium chloride (0.09 g, 0.5 mmol) and N,N-dimethylformamide 2 mL. The resulting solution was warmed to120 °C and stirred at this temperature for 6 h. When the reaction was completed, 25 mL water was added and the resulting mixture was extracted with 25 mL ethyl acetate twice. The combined organic layer was successively washed with H2O (50 mL) and then brine (50 mL), then dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether and ethyl acetate or recrystallized from petroleum ether/EA to give the title products.
Reference: [1] Tetrahedron, 2018, vol. 74, # 52, p. 7450 - 7456
  • 3
  • [ 64-18-6 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
Reference: [1] Synthetic Communications, 2012, vol. 42, # 1, p. 102 - 108
[2] Molecules, 2015, vol. 20, # 8, p. 15206 - 15223
  • 4
  • [ 122-51-0 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
Reference: [1] Synthetic Communications, 2004, vol. 34, # 23, p. 4265 - 4272
  • 5
  • [ 50-00-0 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 7, p. 2620 - 2623
  • 6
  • [ 124-38-9 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
Reference: [1] ChemCatChem, 2018, vol. 10, # 12, p. 2593 - 2600
  • 7
  • [ 67-56-1 ]
  • [ 102-51-2 ]
  • [ 10394-42-0 ]
  • [ 10394-39-5 ]
  • [ 4887-80-3 ]
Reference: [1] Green Chemistry, 2015, vol. 17, # 12, p. 5172 - 5181
  • 8
  • [ 57-55-6 ]
  • [ 102-51-2 ]
  • [ 4887-80-3 ]
  • [ 4887-81-4 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 2010, vol. 83, # 7, p. 831 - 837
  • 9
  • [ 107-21-1 ]
  • [ 102-51-2 ]
  • [ 6639-82-3 ]
  • [ 4887-80-3 ]
  • [ 92050-12-9 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 2010, vol. 83, # 7, p. 831 - 837
  • 10
  • [ 55305-43-6 ]
  • [ 102-51-2 ]
  • [ 6232-91-3 ]
YieldReaction ConditionsOperation in experiment
66% With lithium hexamethyldisilazane In tetrahydrofuran; hexane at 5 - 20℃; for 1 h; Green chemistry General procedure: To a solution of o-aminophenol (400 mg, 3.67 mmol) and NCTS (998 mg, 3.67 mmol) in THF (6 mL), 1 M LiHMDS in hexane (3.67 mL, 3.67 mmol) was added and stirred at 5 °C to r.t. for 1h. Then the reaction mixture was poured in ice water and stirred for 15 min. Then extracted with EtOAc, the organic layer was separated. The organic layer was washed with brine solution.Then organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtained pure 2-aminobenzaxozole in 90percent yield (471 mg).
Reference: [1] Synlett, 2015, vol. 26, # 7, p. 897 - 900
  • 11
  • [ 506-68-3 ]
  • [ 102-51-2 ]
  • [ 6232-91-3 ]
Reference: [1] Angewandte Chemie - International Edition, 2012, vol. 51, # 21, p. 5226 - 5229
[2] European Journal of Medicinal Chemistry, 1991, vol. 26, # 6, p. 633 - 642
[3] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 23, p. 270
[4] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 11, p. 2842 - 2845
[5] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 23, p. 270
  • 12
  • [ 103-82-2 ]
  • [ 102-51-2 ]
  • [ 40608-76-2 ]
YieldReaction ConditionsOperation in experiment
67% With boric acid In 5,5-dimethyl-1,3-cyclohexadiene for 16 h; Reflux General procedure: To a stirred solution of benzene-1,2-diamine 1 (1.85 mmol)in xylenes (10 mL) were added carboxylic acid 2 (2.77 mmol)and boric acid (0.185 mmol). The resulting solution wasrefluxed for 16 h. After cooling to room temperature, the reactionwas concentrated under reduced pressure and diluted withEtOAc (50 mL). The organic phase was washed with saturatedNaHCO3 solution (2 50 mL), dried over anhydrous Na2SO4and then concentrated under reduced pressure. The residuewas purified by silica gel flash column chromatography (elutingwith 10–15percent Ethyl acetate in hexanes) to afford the title compounds3a–y and 5.6.2.21
2-Benzyl-5-methoxy-1H-benzo[d]imidazole (3u)
Yield 67percent; Off white solid; mp 109-111 °C; IR (KBr) 3009, 2847, 1510, 1466, 1410, 1248, 1175, 1029, 775 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.04-12.14 (m, 1H), 7.18-7.44 (m, 6H), 6.91 - 7.07 (m, 1H), 6.70-6.79 (m, 1H), 4.12 (s, 2H), 3.75 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 155.5, 137.9, 128.8, 128.5, 126.6, 118.7, 110.1, 101.3, 94.5, 55.4, 34.9; HRMS calcd for C15H14N2O m/z 238.1182, found 238.1180.
Reference: [1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 8, p. 1872 - 1878
[2] Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1545,1550[3] J. Gen. Chem. USSR (Engl. Transl.), 1949, vol. 19, p. 1555
  • 13
  • [ 122-78-1 ]
  • [ 102-51-2 ]
  • [ 40608-76-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 7, p. 2620 - 2623
  • 14
  • [ 102-51-2 ]
  • [ 27799-91-3 ]
Reference: [1] European Journal of Medicinal Chemistry, 2010, vol. 45, # 6, p. 2214 - 2222
[2] Journal of the American Chemical Society, 1953, vol. 75, p. 715,717
  • 15
  • [ 102-51-2 ]
  • [ 27799-91-3 ]
Reference: [1] Organic and Biomolecular Chemistry, 2014, vol. 12, # 2, p. 251 - 254
  • 16
  • [ 67-56-1 ]
  • [ 102-51-2 ]
  • [ 10394-42-0 ]
  • [ 10394-39-5 ]
  • [ 4887-80-3 ]
Reference: [1] Green Chemistry, 2015, vol. 17, # 12, p. 5172 - 5181
  • 17
  • [ 924-44-7 ]
  • [ 102-51-2 ]
  • [ 55687-11-1 ]
YieldReaction ConditionsOperation in experiment
35%
Stage #2: for 1 h; Reflux
Step A: 7-Methoxyqu lin-2(lH)-oneA 50percent solution of ethyl 2-oxoacetate (18.47 mL, 93 mmol) in toluene was added to a solution of 4-methoxybenzene-l,2-diamine (10.73 g, 78 mmol) in ethanol (100 mL) at ambient temperature and the reaction was refluxed for 2 h. The reaction was concentrated in vacuo and crystallized from ethanol to afford a mixture of 6- methoxyquinoxalin-2(lH)-one and 7-methoxyquinoxalin-2(lH)-one (5.73 g, 32.50 mmol, 42 percent yield). MS (LC/MS) R.T. = 0.68; [M+H]+ = 177.10.
35%
Stage #1: at 20℃; for 2 h; Reflux
Stage #2: for 1 h; Reflux
50percent solution of ethyl2-oxoacetate (18.47 ml., 93mmol) in toluene was added to a solution of 4-methoxybenzene-I,2-diamine (10.73 g, 78 mmol) in ethanol (100 mL) at ambient temperature and the reaction was ref/uxed for 2 h.The reaction was concentrated in vacuo and crystallized fromethanol to afford a mixture of 6-methoxyquinoxalin-2(1H)oneand 7-methoxyquinoxalin-2(1H)-one (5.73 g, 32.50mmol, 42percent yield). A mixture of 6-methoxyquinoxalin-2(1H)-one and7-methoxyquinoxalin-2(1H)-one (5.67 g, 32.20 mmol) wasrefluxed in phosphorus oxychloride (120 mL) for I h. Thereaction was concentrated and quenched by addition of ice,then basified with sodium carbonate, and extracted with ethylacetate (3x200 mL). The organic layers were combined andconcentrated in vacuo. The crude product was absorbed ontosodium sulfate and purified by column chromatography (0 to5percent ethyl acetatelhexanes) to afford 2-chloro-6-methoxyquinoxaline(2.21 g, 11.36 mmol, 35percent yield).
Reference: [1] Patent: WO2011/53292, 2011, A1, . Location in patent: Page/Page column 147
[2] Patent: JP5714745, 2015, B2, . Location in patent: Paragraph 0296; 0297; 0298
  • 18
  • [ 924-44-7 ]
  • [ 102-51-2 ]
  • [ 55686-93-6 ]
  • [ 55687-11-1 ]
YieldReaction ConditionsOperation in experiment
34.7%
Stage #1: Reflux
Stage #2: for 3 h; Reflux
To a solution of 4-methoxybenzene-1,2-diamine (5 g, 36.2 mmol) in ethanol (50 ml) was added ethyl 2-oxoacetate (4.06 g, 39.8 mmol)). The reaction mass was heated at reflux for overnight. The solvent was evaporated under reduced pressure and the residue was diluted with ethyl acetate and then evaporated to dryness to get the crude compound. The crude compound was washed with pet ether to get crude compound (5.1 g, 80percent yield) as a mixture of regioisomers (black solid). This crude compound was taken to the next step without separation of isomers.1H NMR (400 MHz, DMSO-d6): δ ppm 8.17 (s, 1H), 7.98 (s, 1H), 7.70-7.68 (d, J=8 Hz, 1H), 7.31-7.30 (d, J=4 Hz, 1H), 7.27-7.20 (m, 2H), 6.93-6.90 (m, 1H), 6.77-6.76 (d, J=4 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H); MS: MS m/z 177.0 (M++1). A solution of 6-methoxyquinoxalin-2(1H)-one & 7-methoxyquinoxalin-2(1H)-one (3 g, 18.28 mmol) in POCl3(20 ml) was refluxed for 3 h. The solvent was evaporated under reduced pressure and the residue was diluted with cold water. The aqueous solution was basified by solid sodium carbonate and extracted with ethyl acetate. The combine organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to get crude compound. The crude compound was purified by silica gel chromatography (20percent ethyl acetate in pet ether) to afford mixture of regioisomers (3.7 g). 2 g of the above mixture was separated by SFC purification to afford 2-chloro-7-methoxyquinoxaline (0.7 g, 34.7percent) and 2-chloro-7-methoxyquinoxaline (0.9 g, 44.6percent) as off white solid.2-chloro-6-methoxyquinoxaline:1H NMR (400 MHz, DMSO-d6): δ ppm1H NMR (400 MHz, CDCl3): δ ppm 8.71 (s, 1H), 7.91-7.89 (d, J=8 Hz, 1H), 7.46-7.38 (m, 2H), 3.97 (s, 3H); MS: MS m/z 194.9 (M++1).2-chloro-7-methoxyquinoxaline:1H NMR (400 MHz, CDCl3): δ ppm 8.63 (s, 1H), 7.99-7.96 (d, J=12 Hz, 1H), 7.43-7.40 (d, J=12 Hz, 1H), 7.30 (s, 1H), 3.96 (s, 3H); MS: MS m/z 194.9 (M++1).
150 mg
Stage #1: for 2 h; Reflux
Stage #2: for 1 h; Reflux
To a solution of 4-methoxybenzene-1,2-diamine (3.58 g, 25.9 mmol) in dry EtOH (30 mL) was added 50percent ethyl 2-oxoacetate in toluene (6.2 mL) and the mixture was heated under reflux for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was washed with EtOH to give a mixture of 6-methoxyquinoxalin-2-ol and 7-methoxyquinoxalin-2-ol as a brown solid (2.6 g, 57percent). 1H NMR (300 MHz, DMSO-d612.30 (s, 1H), 8.13 (s, 1H), 7.23-7.25 (m, 1H), 7.15-7.20 (m, 2H), 3.78 (s, 3H). LC-MS (ESI) mlz 177 (M+H)+. [000179] Step 2: The mixture of 6-methoxyquinoxalin-2-ol and 7-methoxyquinoxalin-2-ol (1.6 g, 9.1 mmol) in POC13 (30 mL) was heated under reflux for 1 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure. The residue was quenched with ice, basified with saturated aq Na2CO3, and extracted with EtOAc. The organic layer was dried over Na2504, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with 3percent EtOAc in petroleum ether to give the following products:[000180] Pure 2-chloro-6-methoxyquinoxaline as a white solid (150 mg), 1H NMR (300 MHz, CDC13 8.71 (s, 1H), 7.90 (d, J = 9.3 Hz, 1H), 7.44 (dd, J = 9.3, 2.7 Hz, 1H), 7.37 (d, J = 2.7 Hz, 1H), 3.95 (s, 3H). LC-MS (ESI) mlz 195 (M+H)+.[000181] Pure 2-chloro-7-methoxyquinoxaline as a white solid (100 mg). 1H NMR (300 MHz, CDC13 8.62 (s, 1H), 7.97 (d, J = 9.3 Hz, 1H), 7.41 (dd, J = 9.3, 2.7 Hz, 1H), 7.29 (d, J = 2.7 Hz, 1H), 3.96 (s, 3H). LC-MS (ESI) mlz 195 (M+H)+.[000182] A mixture of 2-chloro-6-methoxy quinoxaline and 2-chloro-7- methoxyquinoxaline as a white solid (1.27 g, 85percent).
Reference: [1] Patent: US9527885, 2016, B2, . Location in patent: Page/Page column 613; 614
[2] Patent: WO2015/31613, 2015, A1, . Location in patent: Paragraph 000178 - 000182
  • 19
  • [ 6295-06-3 ]
  • [ 102-51-2 ]
  • [ 55687-11-1 ]
Reference: [1] Journal of the American Chemical Society, 1949, vol. 71, p. 6,7
  • 20
  • [ 298-12-4 ]
  • [ 102-51-2 ]
  • [ 55686-93-6 ]
  • [ 55687-11-1 ]
Reference: [1] Journal of the Chemical Society. Perkin Transactions 1, 2001, # 9, p. 978 - 984
  • 21
  • [ 102-51-2 ]
  • [ 13311-79-0 ]
Reference: [1] Journal of the American Chemical Society, 1947, vol. 69, p. 795,796
  • 22
  • [ 32315-10-9 ]
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2016, vol. 7, # 6, p. 552 - 557
  • 23
  • [ 623-49-4 ]
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] Letters in Organic Chemistry, 2011, vol. 8, # 6, p. 406 - 411
  • 24
  • [ 124-38-9 ]
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] Chemistry - An Asian Journal, 2016, vol. 11, # 19, p. 2735 - 2740
  • 25
  • [ 57-13-6 ]
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] MedChemComm, 2013, vol. 4, # 3, p. 527 - 529
  • 26
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] Patent: WO2012/3418, 2012, A2,
[2] Letters in Organic Chemistry, 2011, vol. 8, # 6, p. 406 - 411
  • 27
  • [ 530-62-1 ]
  • [ 102-51-2 ]
  • [ 2080-75-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 3, p. 719 - 723
  • 28
  • [ 102-51-2 ]
  • [ 39267-04-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1990, vol. 33, # 8, p. 2240 - 2254
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4508 - 4522
[3] Patent: WO2014/145095, 2014, A1,
[4] Patent: WO2017/37604, 2017, A1,
[5] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 7, p. 1809 - 1814
  • 29
  • [ 924-44-7 ]
  • [ 102-51-2 ]
  • [ 55687-30-4 ]
  • [ 91192-32-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 21, p. 3153 - 3156
[2] Patent: US2009/270405, 2009, A1, . Location in patent: Page/Page column 89
[3] Patent: US9527885, 2016, B2, . Location in patent: Page/Page column 613
[4] Patent: JP5714745, 2015, B2, . Location in patent: Paragraph 0296; 0297
[5] Patent: WO2006/134378, 2006, A1, . Location in patent: Page/Page column 133-134
  • 30
  • [ 298-12-4 ]
  • [ 102-51-2 ]
  • [ 55687-30-4 ]
  • [ 91192-32-4 ]
Reference: [1] Journal of the Chemical Society. Perkin Transactions 1, 2001, # 9, p. 978 - 984
  • 31
  • [ 3395-03-7 ]
  • [ 102-51-2 ]
  • [ 27841-33-4 ]
Reference: [1] Patent: US6218415, 2001, B1,
  • 32
  • [ 96-96-8 ]
  • [ 102-51-2 ]
YieldReaction ConditionsOperation in experiment
99% With palladium 10% on activated carbon; hydrogen In ethanol at 20℃; for 24 h; Approximately 360 mg (2.14 mmol) of 4-methoxy-2-nitroanniline was placed in a hydrogenator and 65 mL ethanol was added. A pinch of 10percent palladium on activated carbon was added and the reaction mixture hydrogenated at room temperature under 50 Psi pressure for 24 hrs. The reaction mixture was filtered and concentrated on rotovap to give TZ10-55 as dark purple oil (294 mg, 2.12 mmol, 99percent). 1HNMR (CDCl3): δ 6.64 (d, J=8.7 Hz, 1H), 6.35-6.30 (m, 1H), 6.26 (d, J=8.7 Hz, 1H), 3.52 (s br, 2H), 3.07 (s br, 2H).
97% With hydrogen In methanol at 20℃; Example 68: T-chloro-B-oxo-B^-dihydro^H-benzon^lthiazine--carboxylic acid {1- [2-f7-methoxy-3-methyl-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl}-amide: Preparation of 4-methoxy-benzene-l ,2-diamine: 10percent Palladium on activated carbon (1.0 g, 9.4 mmol, 0.15 eq) is added at room temperature to a stirred solution of 4-methoxy-2-nitro-phenylamine (10.0 g, 59.5 mmol, 1.0 eq) in methanol (70 mL). The mixture is hydrogenated for 72 hours, then filtered through decalite. Solvent is removed to afford 4-methoxy-benzene-l,2-diamine as a dark brown oil (8.0 g, 97percent yield).1H-NMR (400 MHz, MeOH-t/4) δ ppm: 6.62 (d, J = 8.4 Hz, IH), 6.34 (d, J = 2.8 Hz, IH), 6.18 (dd, J = 2.8, 8.4 Hz, IH), 3.82 (s, 3H).
84.5% With iron; ammonium chloride In ethanol; water for 24 h; Reflux To a stirred solution of 4-methoxy-2-nitroaniline (8.7 g, 51.73 mmol) in EtOHJH2O(3:1, 105 mL) was added portion wise Fe powder (20.5 g, 36.73 mmol) followed byNH4C1 at room temperature. The reaction mixture was heated at reflex for 24h. Aftercompletion of the reaction, filtered through a small pad of Celite and washed withEtOH (3 X 30 mL), solvent was evaporated under reduced pressure. The obtainedcrude was dissolved in H20 (50 mL) and extracted with EtoAc (3 X 60 mL). Thecombined organic layers were dried over anhydrous Na2504, filtered and concentrated under reduced pressure to get a 84.5 percent yield of dark brown colour solid, which was used in the next step without any further purification. ‘H NMR (500 MHz, DMSO-d6):5 6.50 (d, 1H), 6.20 (d, 1H), 6.00 (dd, 1H), 3.50 (s, 3H). LC-MS [mlz]: 139.2 [M+H],91.670percent purity.
72.5% With palladium on activated charcoal; hydrogen In methanol at 50℃; To a mixture of compound 1 (33.6 g, 0.020 mol) and Pd/C (6.72 g) in MeOH (400 mL) was hydrogenated under 50 psi of H2 at 50° C. for 3 h. The catalyst was filtered off and the filtrate was concentrated to give the residue then purified by column chromatography on silica gel to give compound 2 (20 g, 72.5percent) as reddish solid.
69% With iron; ammonium chloride In ethanol; waterReflux Intermediate 35:[0166] To a solution of 4-methoxy-2-nitroaniline (10 g, 59.4 mmol) in EtOH (200 mL) and water (80 mL) was added iron (12 g, 210 mmol) and ammonium chloride (9.63 g, 180 mmol). The mixture was then heated to reflux and stirred overnight. The mixture was filtered and the filtrate was evaporated to remove the EtOH and the residue was purified by flash chromatography on silica gel column (elution with DCM/MeOH = 80:1) to give 4- methoxybenzene-l,2-diamine (intermediate 35) (5.65 g, 69percent) as a yellow solid.
95 %Chromat. With hydrazine hydrate In ethanol at 80℃; for 1 h; Inert atmosphere General procedure: Hydrazine hydrate was chosen as the hydrogen donor for the low emission of pollutants. In a typical procedure, hydrazine hydrate (4 equiv) was added into the reactor which containing fresh prepared catalyst as described above. Then the reactor was put into a preheated oil bath with a stirring speed of 500 rpm, and the substrate (1 mmol)dissolved in 1 mL ethanol was added drop-wisely under argon. The reactions were monitored by TLC. After the reaction, the reaction mixture was vacuum filtered through a pad of silica on a glass-fritted funnel and an additional 15 mL of ethyl acetate (5 mL portions) was used to rinse the product from the silica, the filtrate was concentrated in vacuum and analyzed by GC. Products were purified by column chromatography and identified by 1H NMR and 13C NMR.

Reference: [1] Patent: US2013/315825, 2013, A1, . Location in patent: Paragraph 0220
[2] Patent: WO2010/84152, 2010, A1, . Location in patent: Page/Page column 109-110
[3] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[4] RSC Advances, 2015, vol. 5, # 78, p. 63421 - 63428
[5] Patent: WO2017/37604, 2017, A1, . Location in patent: Page/Page column 25
[6] Patent: JP2015/214548, 2015, A, . Location in patent: Paragraph 1288; 1289
[7] RSC Advances, 2018, vol. 8, # 12, p. 6288 - 6292
[8] Patent: WO2012/3418, 2012, A2, . Location in patent: Page/Page column 70
[9] European Journal of Medicinal Chemistry, 1991, vol. 26, # 6, p. 633 - 642
[10] Chemical Communications, 2014, vol. 50, # 56, p. 7469 - 7472
[11] Journal of the American Chemical Society, 1947, vol. 69, p. 795,796
[12] Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1545,1550[13] J. Gen. Chem. USSR (Engl. Transl.), 1949, vol. 19, p. 1555
[14] Journal of the American Chemical Society, 1947, vol. 69, p. 795,796
[15] Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1545,1550[16] J. Gen. Chem. USSR (Engl. Transl.), 1949, vol. 19, p. 1555
[17] Journal of the Chemical Society, 1948, p. 1719
[18] Journal of the American Chemical Society, 1947, vol. 69, p. 583,58
[19] Acta Chemica Scandinavica, 1992, vol. 46, # 11, p. 1109 - 1113
[20] Farmaco, 1994, vol. 49, # 10, p. 671 - 674
[21] Bioorganic and Medicinal Chemistry, 1998, vol. 6, # 2, p. 163 - 172
[22] Journal of the American Chemical Society, 2006, vol. 128, # 26, p. 8569 - 8574
[23] Tetrahedron Letters, 2006, vol. 47, # 30, p. 5359 - 5361
[24] Journal of Heterocyclic Chemistry, 2009, vol. 46, # 2, p. 221 - 225
[25] Journal of Medicinal Chemistry, 2010, vol. 53, # 21, p. 7664 - 7674
[26] Journal of the American Chemical Society, 2012, vol. 134, # 18, p. 7604 - 7607
[27] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 17, p. 4790 - 4793
[28] Asian Journal of Chemistry, 2013, vol. 25, # 14, p. 7959 - 7966
[29] Dyes and Pigments, 2013, vol. 99, # 3, p. 1132 - 1136
[30] Journal of the Serbian Chemical Society, 2014, vol. 79, # 3, p. 277 - 282
[31] Molecules, 2014, vol. 19, # 7, p. 9736 - 9759
[32] Patent: WO2014/145095, 2014, A1, . Location in patent: Page/Page column 106
[33] ChemMedChem, 2015, vol. 10, # 3, p. 511 - 522
[34] Patent: WO2015/95430, 2015, A1, . Location in patent: Page/Page column 52
[35] Tetrahedron Letters, 2015, vol. 56, # 48, p. 6762 - 6767
[36] Organic Letters, 2016, vol. 18, # 9, p. 1952 - 1955
[37] Catalysis Communications, 2016, vol. 84, p. 25 - 29
[38] Patent: CN106212487, 2016, A, . Location in patent: Paragraph 0032
[39] Patent: CN106243110, 2016, A, . Location in patent: Paragraph 0027; 0028
[40] Patent: CN104710815, 2017, B, . Location in patent: Paragraph 0059; 0060; 0061
[41] Patent: CN104710817, 2017, B, . Location in patent: Paragraph 0052-0055
[42] Patent: CN104710816, 2017, B, . Location in patent: Paragraph 0054; 0055; 0056; 0057
  • 33
  • [ 16133-49-6 ]
  • [ 102-51-2 ]
YieldReaction ConditionsOperation in experiment
24 g With palladium 10% on activated carbon; hydrogen In methanol 32 g of 5-methoxy-2-nitroaniline was added to 350 ml of methanol, 3.2 g of 10percent palladium carbon was added, hydrogen was bubbled in, stirred overnight, filtered, the filtrate was collected, and concentrated to give 24 g of 4-methoxy-1 2-diphenylamine.
Reference: [1] Journal of Heterocyclic Chemistry, 1987, vol. 24, # 6, p. 1771 - 1775
[2] Synthetic Communications, 2007, vol. 37, # 19, p. 3455 - 3470
[3] Journal of Heterocyclic Chemistry, 2012, vol. 49, # 5, p. 1196 - 1201
[4] Patent: JP2016/175996, 2016, A, . Location in patent: Paragraph 0147-0148
[5] Patent: CN106234372, 2016, A, . Location in patent: Paragraph 0027
[6] Patent: JP2016/172816, 2016, A, . Location in patent: Paragraph 0112-0113
[7] Patent: CN106220575, 2016, A, . Location in patent: Paragraph 0025; 0026
[8] Journal of Medicinal Chemistry, 2017, vol. 60, # 14, p. 6289 - 6304
[9] Patent: CN107778252, 2018, A, . Location in patent: Paragraph 0020-0022
  • 34
  • [ 16554-45-3 ]
  • [ 102-51-2 ]
Reference: [1] Patent: JP5670893, 2015, B2, . Location in patent: Paragraph 0245; 0246
  • 35
  • [ 10336-13-7 ]
  • [ 102-51-2 ]
Reference: [1] Synthesis, 2001, # 1, p. 81 - 84
  • 36
  • [ 62415-74-1 ]
  • [ 102-51-2 ]
Reference: [1] Journal of Organic Chemistry, 2012, vol. 77, # 15, p. 6653 - 6656
  • 37
  • [ 4280-28-8 ]
  • [ 102-51-2 ]
Reference: [1] Journal of the American Chemical Society, 1958, vol. 80, p. 1662
  • 38
  • [ 119-81-3 ]
  • [ 102-51-2 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[3] Asian Journal of Chemistry, 2013, vol. 25, # 14, p. 7959 - 7966
[4] Patent: WO2017/37604, 2017, A1,
  • 39
  • [ 51-66-1 ]
  • [ 102-51-2 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[3] Asian Journal of Chemistry, 2013, vol. 25, # 14, p. 7959 - 7966
[4] Patent: WO2017/37604, 2017, A1,
  • 40
  • [ 104-94-9 ]
  • [ 102-51-2 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[3] Asian Journal of Chemistry, 2013, vol. 25, # 14, p. 7959 - 7966
[4] Patent: WO2017/37604, 2017, A1,
  • 41
  • [ 5228-61-5 ]
  • [ 102-51-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 17, p. 4790 - 4793
  • 42
  • [ 102-51-2 ]
  • [ 3694-52-8 ]
Reference: [1] Acta Chemica Scandinavica, 1992, vol. 46, # 11, p. 1109 - 1113
  • 43
  • [ 102-51-2 ]
  • [ 37052-78-1 ]
YieldReaction ConditionsOperation in experiment
63% With potassium hydroxide In CS2; ethanol; water EXAMPLE 4
2-[(3,7-Dimethyl-2,6(E)-octadienyl)thio]-5-methoxy-1H-1,3-benzimidazole Monooxalate
To potassium hydroxide (3.8 g, 0.067M) in ethanol (20 mL) and water (7 mL) was added 2.5 mL CS2 (3.09 g, 0.04M) (H2 S trapped over clorox).
The reaction mixture was stirred for 30 minutes at ambient temperature, cooled to 0° C., and 4-methoxy-o-phenylene diamine (5.23 g, 0.03M) was slowly added.
This reaction mixture was then stirred at reflux for 4 hours, stirred at ambient temperature overnight (basic soln. with pH paper), evaporated in vacuo and diluted with CH2 Cl2.
Addition of water gave a precipitate which was suspended in CH2 Cl2 and acidified to pH 4.
Filtration of the suspension gave purple crystalline 5-methoxy-2-mercaptobenzimidazole (3.4 g, 63percent).
Reference: [1] Patent: US5106863, 1992, A,
  • 44
  • [ 75-15-0 ]
  • [ 102-51-2 ]
  • [ 37052-78-1 ]
Reference: [1] Medicinal Chemistry Research, 2014, vol. 23, # 3, p. 1290 - 1299
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 7, p. 1756 - 1758
[3] European Journal of Medicinal Chemistry, 2003, vol. 38, # 9, p. 811 - 824
  • 45
  • [ 140-89-6 ]
  • [ 102-51-2 ]
  • [ 37052-78-1 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1989, vol. 37, # 6, p. 1517 - 1523
  • 46
  • [ 140-92-1 ]
  • [ 102-51-2 ]
  • [ 37052-78-1 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2012, vol. 51, # 11, p. 1619 - 1622
  • 47
  • [ 63467-57-2 ]
  • [ 102-51-2 ]
  • [ 37052-78-1 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2012, vol. 51, # 11, p. 1619 - 1622
Same Skeleton Products
Historical Records